{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:11:59Z","timestamp":1791994319237,"version":"4.4.0"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007923","name":"University of Wisconsin Carbone Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007923","id-type":"DOI","asserted-by":"publisher"}]},{"name":"JD Fluno Colorectal Cancer Precision Medicine Program"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Trifluridine-tipiracil (TAS-102) is approved as monotherapy and in combination with bevacizumab for refractory unresectable metastatic colorectal cancer (mCRC). The recommended dose is 35 mg\/m2 twice daily on days 1-5 and days 8-12 of 28-day cycles commonly resulting in grade 3-4 neutropenia, dose delays\/reductions, and requiring GCSF support. To maintain efficacy and reduce toxicity, we analyzed a biweekly dosing schedule (days 1-5 and days 15-19 q28 days).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and Methods<\/jats:title>\n                  <jats:p>A retrospective analysis was performed in patients with mCRC and appendiceal cancer who completed &amp;gt;12 days of TAS-102 therapy and underwent surveillance imaging every 8-12 weeks. ECOG performance status (PS), prior lines of therapy, use of bevacizumab, CTCAE grade of treatment-related myelotoxicity, dose reductions\/delays, and use of GCSF were assessed. Among patients with mCRC, survival analyses were performed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>61 patients met inclusion criteria, with mCRC:appendiceal CA ratio of 56:5. Median ECOG PS\u2005=\u20051; median number of prior therapies\u2005=\u20053; Reduction in grade \u22653 neutropenia (16.3%, 1 patient with grade 4) and grade \u22653 anemia (8.2%) relative to the historic controls of the RECOURSE and SUNLIGHT trials. No neutropenic fever was noted; GCSF was not required. Eight patients required a dose delay. In the mCRC patients, the median progression-free survival (PFS) was 4.2 months, with a median overall survival (OS) of 9.2 months.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Biweekly dosing of TAS-102 demonstrated a reduction in myelosuppression, with similar PFS and OS. With an improved toxicity profile, this alternative dosing schedule may potentially broaden the utilization of TAS-102 in patients with borderline PS and provide a favorable option for future combination studies.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf099","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T11:37:06Z","timestamp":1748345826000},"source":"Crossref","is-referenced-by-count":6,"title":["Biweekly dosing of trifluridine-tipiracil reduces rates of myelosuppression while maintaining efficacy in patients with metastatic colorectal cancer"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6960-6460","authenticated-orcid":false,"given":"Christopher","family":"Cann","sequence":"first","affiliation":[{"name":"Fox Chase Cancer Center, Department of Hematology and Oncology , Philadelphia, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6078-0561","authenticated-orcid":false,"given":"Michael","family":"LaPelusa","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center, Division of Hematology and Oncology , Nashville, TN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Cimino","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center, Division of Hematology and Oncology , Nashville, TN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Cancelliere","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center, Division of Hematology, Medical Oncology and Palliative Care , Madison, WI ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Dow-Hillgartner","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center, Division of Hematology, Medical Oncology and Palliative Care , Madison, WI ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiguo","family":"Zhao","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center, Division of Hematology and Oncology , Nashville, TN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dustin","family":"Deming","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center, Division of Hematology, Medical Oncology and Palliative Care , Madison, WI ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2335-0612","authenticated-orcid":false,"given":"Cathy","family":"Eng","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center, Division of Hematology and Oncology , Nashville, TN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"key":"2025052707365625100_CIT0001","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2025052707365625100_CIT0002","doi-asserted-by":"publisher","first-page":"29765","DOI":"10.1038\/srep29765","article-title":"Patterns of metastasis in colon and rectal cancer","volume":"6","author":"Riihimaki","year":"2016","journal-title":"Sci Rep"},{"key":"2025052707365625100_CIT0003","article-title":"SEER cancer stat facts: Colorectal cancer 2025","author":"National Cancer Institute"},{"key":"2025052707365625100_CIT0004","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.clcc.2017.03.019","article-title":"Treatment of patients with metastatic colorectal cancer in a real-world scenario: Probability of receiving second and further lines of therapy and description of clinical benefit","volume":"16","author":"Tampellini","year":"2017","journal-title":"Clin Colorectal Cancer"},{"key":"2025052707365625100_CIT0005","doi-asserted-by":"publisher","first-page":"107823","DOI":"10.1016\/j.pharmthera.2021.107823","article-title":"TAS-102: A resurrected novel Fluoropyrimidine with expanding role in the treatment of gastrointestinal malignancies","volume":"224","author":"Chakrabarti","year":"2021","journal-title":"Pharmacol Ther"},{"key":"2025052707365625100_CIT0006","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1002\/cncr.22125","article-title":"Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors","volume":"107","author":"Hong","year":"2006","journal-title":"Cancer"},{"key":"2025052707365625100_CIT0007","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1080\/07357900802087242","article-title":"Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors","volume":"26","author":"Overman","year":"2008","journal-title":"Cancer Invest"},{"key":"2025052707365625100_CIT0008","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s10637-008-9142-3","article-title":"Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors","volume":"26","author":"Overman","year":"2008","journal-title":"Invest New Drugs"},{"key":"2025052707365625100_CIT0009","doi-asserted-by":"publisher","first-page":"10576","DOI":"10.1200\/jco.2006.24.18_suppl.10576","article-title":"Phase I study to determine the safety of oral administration of TAS-102 on a twice daily (BID) schedule for five days a week (wk) followed by two days rest for two wks, every (Q) four wks in patients (pts) with metastatic breast cancer (MBC)","volume":"24","author":"Green","year":"2006","journal-title":"J Clin Oncol"},{"key":"2025052707365625100_CIT0010","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.30.15_suppl.3631","article-title":"phase I dose-escalation study of TAS-102 in patients (pts) with refractory metastatic colorectal cancer (mCRC)","volume":"30","author":"Patel","year":"2012","journal-title":"J Clin Oncol"},{"key":"2025052707365625100_CIT0011","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N Engl J Med"},{"key":"2025052707365625100_CIT0012","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/S1470-2045(12)70345-5","article-title":"TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial","volume":"13","author":"Yoshino","year":"2012","journal-title":"Lancet Oncol"},{"key":"2025052707365625100_CIT0013","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","article-title":"Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer","volume":"388","author":"Prager","year":"2023","journal-title":"N Engl J Med"},{"key":"2025052707365625100_CIT0014","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ejca.2017.10.009","article-title":"The subgroups of the phase III RECOURSE trial of trifluridine\/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer","volume":"90","author":"Van Cutsem","year":"2018","journal-title":"Eur J Cancer"},{"key":"2025052707365625100_CIT0015","article-title":"The R project for statistical computing","author":"Foundation R","year":"2023"},{"key":"2025052707365625100_CIT0016","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.tmrv.2008.05.005","article-title":"Granulocyte colony-stimulating factor administration: adverse events","volume":"22","author":"D\u2019Souza","year":"2008","journal-title":"Transfus Med Rev"},{"key":"2025052707365625100_CIT0017","doi-asserted-by":"publisher","first-page":"4367","DOI":"10.21873\/anticanres.12738","article-title":"Biweekly administration of TAS-102 for neutropenia prevention in patients with colorectal cancer","volume":"38","author":"Yoshida","year":"2018","journal-title":"Anticancer Res"},{"key":"2025052707365625100_CIT0018","doi-asserted-by":"publisher","first-page":"e1855","DOI":"10.1634\/theoncologist.2020-0643","article-title":"Phase Ib\/II study of biweekly TAS-102 in combination with bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (BiTS Study)","volume":"25","author":"Satake","year":"2020","journal-title":"Oncologist"},{"key":"2025052707365625100_CIT0019","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.21873\/anticanres.14988","article-title":"Prospective multicenter phase II study of biweekly TAS-102 and bevacizumab for metastatic colorectal cancer","volume":"41","author":"Ishizaki","year":"2021","journal-title":"Anticancer Res"},{"key":"2025052707365625100_CIT0020","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1007\/s10147-022-02243-4","article-title":"Biweekly TAS-102 and bevacizumab as third-line chemotherapy for advanced or recurrent colorectal cancer: a phase II, multicenter, clinical trial (TAS-CC4 study)","volume":"27","author":"Matsuoka","year":"2022","journal-title":"Int J Clin Oncol"},{"key":"2025052707365625100_CIT0021","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1200\/JCO.2024.42.3_suppl.118","article-title":"First report of the randomized phase III study of bi-weekly trifluridine\/tipiracil (FTD\/TPI) plus bevacizumab (BEV) vs. FTD\/TPI monotherapy for chemorefractory metastatic colorectal cancer (mCRC): JCOG2014 (ROBiTS)","volume":"42","author":"Satake","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025052707365625100_CIT0022","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1002\/cncr.33379","article-title":"A phase 1b expansion study of TAS-102 with oxaliplatin for refractory metastatic colorectal cancer","volume":"127","author":"Cecchini","year":"2021","journal-title":"Cancer"},{"key":"2025052707365625100_CIT0023","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.4_suppl.18","article-title":"TAS102 in combination with oxaliplatin (TASOX) for refractory metastatic colorectal cancer","volume":"43","author":"Li","year":"2025","journal-title":"J Clin Oncol"},{"key":"2025052707365625100_CIT0024","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.4_suppl.144","article-title":"Phase II study of TAS-OX (TAS-102 and oxaliplatin) plus bevacizumab for late-line colorectal cancer","volume":"41","author":"Houchster","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025052707365625100_CIT0025","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1038\/s41416-024-02885-3","article-title":"Phase II study of irinotecan, Trifluridine\/tipiracil (TAS-102) plus bevacizumab as a Later-line therapy for patients with metastatic colorectal cancer (mCRC): a prospective single-center explorative study","volume":"131","author":"Li","year":"2024","journal-title":"Br J Cancer"},{"key":"2025052707365625100_CIT0026","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/s41416-024-02845-x","article-title":"TAS-102, Irinotecan, and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO), a phase II clinical trial","volume":"131","author":"Boland","year":"2024","journal-title":"Br J Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/5\/oyaf099\/63370833\/oyaf099.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/5\/oyaf099\/63370833\/oyaf099.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T11:37:07Z","timestamp":1748345827000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf099\/8151386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,8]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf099","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,5]]},"article-number":"oyaf099"}}